Modeling the Interaction between the Microenvironment and Tumor Cells in Brain Tumors

Claudia Pasqualini1, Tatsuya Kozaki2, Marco Bruschi3

  • 1Children and Adolescent Oncology Department, Gustave Roussy, Paris-Saclay University, Villejuif, France.

Neuron
|October 16, 2020
PubMed

Insights

Malignant brain tumors have poor outcomes due to challenges in modeling the brain microenvironment. New models like humanized animals and organoids offer better insights for developing brain cancer therapies, including immunotherapies.

Area of Science:

  • Neuro-oncology
  • Cancer Biology
  • Immunotherapy

Background:

  • Malignant brain tumors have poor prognoses despite advances in other cancer treatments.
  • Current preclinical models struggle to accurately replicate the complex brain microenvironment, hindering therapeutic development, especially for immunotherapies.

Purpose of the Study:

  • To examine brain microenvironment features influenced by tumor biology.
  • To discuss limitations of existing preclinical models for brain cancers.
  • To highlight the potential of complementary models for advancing therapeutic strategies.

Main Methods:

  • Focus on brain microenvironment characteristics affected by tumor biology.
  • Analysis of cellular interactions within the brain tumor microenvironment.
  • Review of current preclinical models and their limitations.

Main Results:

  • The brain microenvironment, including cellular interactions, extracellular matrix, and the blood-brain barrier, presents significant challenges.
  • Existing preclinical models inadequately represent the complexity of brain tumors.
  • Heterogeneity within tumors and across tumor types complicates research.

Conclusions:

  • Advanced models like humanized animals and organoids are crucial for deeper mechanistic insights into brain cancer biology.
  • These complementary models can facilitate more effective testing of therapeutic strategies, including immunotherapies.
  • Improving preclinical models is essential for overcoming the challenges in treating malignant brain tumors.